Respiratory Disease News and Research RSS Feed - Respiratory Disease News and Research

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao. [More]
Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. [More]
Oxygen wristbands: an interview with Dr Gillian Lowrey

Oxygen wristbands: an interview with Dr Gillian Lowrey

Oxygen is delivered with variable flows that administer different concentrations. National guidelines were published in 2009 that provide recommendations about prescribing the oxygen and titrating it to certain target ranges. [More]
Ruthigen, Pulmatrix sign definitive merger agreement

Ruthigen, Pulmatrix sign definitive merger agreement

Ruthigen, Inc., a biopharmaceutical company, and Pulmatrix, Inc., a Lexington, Massachusetts based clinical stage biotechnology company, announced today that on March 13, 2015, they have entered into a definitive merger agreement. [More]
Antibiotic nanoparticles can help treat lung infection, prevent drug resistance

Antibiotic nanoparticles can help treat lung infection, prevent drug resistance

Treating respiratory disease is often difficult because drugs have to cross biological barriers such as respiratory tissue and mucosa, and must therefore be given in large quantities in order for an effective amount to reach the target. [More]
Reducing premature deaths from noncommunicable diseases: an interview with Dr Shanthi Mendis, WHO

Reducing premature deaths from noncommunicable diseases: an interview with Dr Shanthi Mendis, WHO

The main types of NCD are cardiovascular disease, cancer, chronic respiratory diseases and diabetes. These have been identified as the principal conditions for three main reasons. One is that, collectively, they contribute the most to the total disease burden. [More]
Kansas State researchers preparing for next potential influenza strain

Kansas State researchers preparing for next potential influenza strain

As seasonal influenza cases decrease across the United States, Kansas State University researchers are preparing for the next potential virulent strain of flu. [More]
CSL Behring donates protein therapies to World Federation of Hemophilia

CSL Behring donates protein therapies to World Federation of Hemophilia

In recognition of Rare Disease Day and as part of its ongoing commitment to the global bleeding disorders community, CSL Behring announced today that it is donating 2 million international units (IUs) of protein therapies to the World Federation of Hemophilia. [More]
Nurtur earns Wellness and Health Promotion Accreditation from NCQA for wellness services

Nurtur earns Wellness and Health Promotion Accreditation from NCQA for wellness services

Centene Corporation today announced that Nurtur, its health and wellness company serving employers, health plans and government programs, has received a three-year Wellness and Health Promotion Accreditation renewal from the National Committee for Quality Assurance for its wellness services. [More]
World class drug discovery team launches new company to tackle chronic respiratory disease

World class drug discovery team launches new company to tackle chronic respiratory disease

Respiratory diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD) and severe asthma represent a major unmet medical need and a significant health burden in both the developed and developing world. [More]
Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis announced today that the US Food and Drug Administration has granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation is intended to accelerate the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition. [More]
Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

Cumberland Pharmaceuticals Inc. today announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD). [More]
Rare respiratory virus could be linked to severe neurological illness in children

Rare respiratory virus could be linked to severe neurological illness in children

A cluster of children from Colorado in the USA have been treated for muscle weakness or paralysis that may be connected to a nationwide outbreak of a usually rare respiratory virus called enterovirus D68 (EV-D68), one of more than 100 non-polio enteroviruses. [More]
Older users of opioids more likely to become victim of homicide, shows study

Older users of opioids more likely to become victim of homicide, shows study

Older users of opioids such as heroin are 27 times more likely to become a victim of homicide than the general population, a University of Manchester study of almost 200,000 users has found. [More]
Bronchial thermoplasty for severe asthma: an interview with Dr. Rob Niven

Bronchial thermoplasty for severe asthma: an interview with Dr. Rob Niven

Internationally, severe asthma is defined as anybody who is on maximum therapy, which has no measurable side effects, but still have symptoms of persistent asthma. In the UK, that effectively means people who require oral steroids for their asthma two or more times a year. [More]
Leading microbiologist warns of killer fungi’s increasing threat

Leading microbiologist warns of killer fungi’s increasing threat

A leading microbiologist has warned of the increasing threat that killer fungi poses to humans and the environment. [More]
Gene variations predispose mestizo Mexican population to develop severe form of COPD

Gene variations predispose mestizo Mexican population to develop severe form of COPD

A study by Ramcés Falfán-Valencia, researcher at the National Institute of Respiratory Diseases, found that the mestizo Mexican population has a number of variations in certain genes that predispose them to develop the most severe form of chronic obstructive pulmonary disease (COPD). [More]
Scientists to explore biology of human asthma by using slime mould

Scientists to explore biology of human asthma by using slime mould

Scientists from Royal Holloway, University of London, will research the biology of human asthma by using a slime mould, an organism which has no lungs but could hold the key to new treatments. [More]
Excess mortality in schizophrenia ‘not attributable to antipsychotics’

Excess mortality in schizophrenia ‘not attributable to antipsychotics’

The relationship between antipsychotic use and mortality in people with schizophrenia shows a clear U-shape curve, with the highest risk of death seen in those with no antipsychotic exposure, a Swedish cohort study has found. [More]
Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of Hematology (ASH) annual meeting December 6-9, and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 9-13. [More]
Advertisement
Advertisement